SCHEDULE: Armistice Capital Discloses 8.65% Stake in Voyager

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.65% in Voyager Therapeutics, Inc., totaling 4,800,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 4,800,000 shares of Common Stock in Voyager Therapeutics, Inc.
• This represents 8.65% of the outstanding Common Stock of Voyager Therapeutics, Inc.
• The shares are held with shared voting and shared dispositive power by the reporting persons.
• The percentage is based on 55,468,806 shares outstanding as of August 1, 2025, as reported in Voyager Therapeutics' Form 10-Q filed on August 6, 2025.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing itself is a factual disclosure of beneficial ownership. The presence of a significant institutional investor like Armistice Capital, LLC holding an 8.65% stake can be interpreted as a positive signal of confidence in Voyager Therapeutics, Inc.'s value proposition, although the filing explicitly states the investment is not for control purposes.

Positives

• A significant stake by an institutional investor like Armistice Capital could signal confidence in Voyager Therapeutics, Inc.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a passive investment rather than an activist intent to disrupt management.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

The disclosure of a significant stake by an investment firm in a biotechnology company like Voyager Therapeutics, Inc. is a common occurrence, reflecting institutional interest in the sector's growth potential, particularly in companies focused on neurological diseases.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership, indicating a significant passive investment. Without specific financial or operational data from Voyager Therapeutics, Inc., a direct comparison to industry-specific benchmarks or competitor performance is not possible based solely on this Schedule 13G.
• However, institutional ownership levels are generally tracked by investors as a sign of market confidence. For example, a similar stake by a hedge fund in a peer like Sarepta Therapeutics or Bluebird Bio would be viewed through the lens of their respective clinical pipelines and market capitalization.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.
• Management: The certification that the investment is not for control purposes suggests no immediate pressure on current management or strategic direction from this specific investor.

Next Steps

• This filing does not outline any specific future actions or milestones for Voyager Therapeutics, Inc. or the reporting persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Armistice Capital, LLC in Voyager Therapeutics, Inc. is a positive indicator of investor confidence, this Schedule 13G filing alone does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. It primarily serves as a transparency report on ownership. A seasoned investor would need to combine this information with the company's latest financial reports, clinical pipeline updates, market conditions, and competitive landscape before making a definitive investment decision. Therefore, a 'hold' recommendation is appropriate until further comprehensive analysis can be conducted.

Keywords

Voyager Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceutical